Please ensure Javascript is enabled for purposes of website accessibility

Why Aimmune Therapeutics Stock Is Soaring Today

By George Budwell – Aug 31, 2020 at 8:35AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Nestle is gobbling up the peanut allergy drugmaker Aimmune Therapeutics for a cool $2.6 billion.

What happened

Shares of Aimmune Therapeutics (AIMT) jumped by an eye-popping 170% in pre-market trading Monday morning. The biotech's stock is screaming higher this morning in response to a $2.6 billion merger agreement -- on a fully diluted basis -- with Nestle's (NSRGY -0.10%) Health Science division (a.k.a NHSc). The deal is expected to close in the fourth quarter of 2020. 

Through this merger, NHSc will acquire the full commercial rights to Aimmune's Food and Drug Administration-approved peanut allergy drug Palforzia. This buyout represents a hefty 74% premium compared to where Aimmune's shares were trading upon market close last Friday.

Two businessmen shaking hands over a table.

Image source: Getty Images.

So what

Digging into the details, Nestle's Health Science division reportedly agreed to pay $34.50 per share in cash in order to acquire the remaining common shares of Aimmune that it did not already own. Prior to this tie-up, NHSc held a 25.6% equity stake in the small-cap drugmaker. 

Although Palforzia's initial commercial launch has gotten off to a sluggish start due to the ongoing pandemic, Wall Street thinks this first-of-its kind peanut allergy medication can eventually achieve blockbuster status (greater than $1 billion in annual sales). If true, Nestle's $2.6 billion investment in Aimmune will turn out to be a flat-out bargain.  

Now what

While Aimmune might have provided a richer return on investment for its shareholders over the long term, this merger agreement is arguably a favorable outcome for its stakeholders. After all, the biotech's stock has been losing value at a breakneck pace since the start of the year, thanks to Palforzia's slower-than-expected rollout. 

George Budwell has no position in any of the stocks mentioned. The Motley Fool recommends Nestle. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Aimmune Therapeutics, Inc. Stock Quote
Aimmune Therapeutics, Inc.
AIMT
Nestle S.A. Stock Quote
Nestle S.A.
NSRGY
$107.50 (-0.10%) $0.11

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
326%
 
S&P 500 Returns
102%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.